INTRODUCTION

Spinal cord injury (SCI), a devastating neurological state, is a major cause of disability.\(^1\) For the last 30 years, the global prevalence of SCI has increased from 236 to 1298 cases per million populations.\(^2\) Results from the Global Burden of Diseases, Injuries and Risk Factors (GBD) Study 2016 showed that there were 27.04 million (95% uncertainty interval, 24.98–30.15 million) patients living with SCI and 0.93 million (95% uncertainty interval, 0.78–1.16 million) new cases diagnosed with SCI across the world in 2016, and this disorder was estimated to cause 9.5 million (95% uncertainty interval, 6.7–12.4 million) years of life lived with disability in 2016.\(^3\) More importantly,
the global number of prevalent cases with SCI is estimated to rise because of the population growth. As a potential risk of developing debilitating and even life-threatening secondary conditions, SCI poses high disease, social and economic burdens throughout the world.5

As a traumatic event, SCI may cause motor, sensory and autonomic dysfunctions, and its pathophysiology comprises acute and chronic phases, and incorporates a cascade of destructive events such as ischaemia, oxidative stress, inflammatory events, apoptotic pathways and locomotor dysfunctions.6 The most vulnerable clinical manifestation after injury is the interruption of spinal cord vascular supply and hypotension, leading to spinal cord ischaemia.7,8 Ischaemia-reperfusion is reported to induce reactive oxygen species production, mitochondrial dysfunction, ion homeostasis imbalance, inflammatory and neural apoptosis,9 and inflammation, oxidative stress response and cytotoxicity could be mediated by microglial cells.10 It has been reported that microglia is activated in mouse spinal cord following ischaemia-reperfusion treatment, and minocycline, a macrolide antibiotic, was found to inhibit microglial activation, preserve hind limb motor function and restrain inflammatory factor production in mice with spinal cord ischaemia-reperfusion injury (SCI).11 Microglia is therefore hypothesized as a therapeutic target for SCI.

Stress-induced phosphoprotein 1 (STIP1), is an adaptor protein that assists the transfer of protein from heat shock protein 70 (HSP70) to HSP90 by binding both HSP90 and substrate-bound HSP70.12,13 It has been found to bind to other chaperones and modulate their activities in addition to HSP70 and HSP90, and aberrant STIP1 expression has been shown to lead to unfolding protein responses.14–16 STIP1 was reported to bind to prion protein to inhibit binding of soluble amyloid-β oligomers to prion protein or mouse primary hippocampal neurons, and STIP1 treatment prevents amyloid-β-induced synaptic loss and neuronal death in mouse cultured neurons and long-term potentiation inhibition in mouse hippocampal specimens.17 In addition, elevated STIP1 expression was detected in cerebral specimens of humans and rats with ischaemic stroke, and STIP1 overexpression promoted recruitment of bone marrow–derived cells to ischaemic brain, and facilitated neurological recovery.18 In heterozygous STIP1 knockout mice, aggravated ischaemic damage was seen in brain, and extracellular STIP1 treatment prevented ischaemia-mediated neuronal cell death, indicating the neuronal protective role of STIP1.19 Recently, STIP1 expression was found to be increased firstly followed by a decrease in rabbit spinal cord specimens after SCI,20 suggesting that STIP may be involved in SCI. However, the effect of STIP1 on SCI remains unclear until now. This study was therefore designed with aims to examine the role of STIP1 in SCI and unravel the possible mechanisms.

2 | MATERIALS AND METHODS

2.1 | Cell culture and treatment

Mouse microglia BV2 cells were purchased from Procell (Wuhan, China), and cultured with minimum essential medium (Sigma-Aldrich; St. Louis, MO, USA) supplemented with 10% foetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) in a homothermal incubator containing 5% CO₂. For oxygen and glucose deprivation (OGD) treatment, cells were incubated in glucose-free medium (Sigma-Aldrich, St. Louis, MO, USA) with 95% N₂ and 5% CO₂ for 6 h, and recovered for 24 h.

2.2 | Animal modelling and grouping

Healthy 8-week-old male rats of the SD strain were purchased from the Laboratory Animal Center of Yangzhou University (Yangzhou, China) and housed in a SPF-grade facility under controlled conditions (12 h/12 h light/dark cycles, 22 ± 1°C) with free access to food and water. After acclimatization for 1 week, rats underwent SCI surgery as described previously.21 Prior to surgery, rats were randomly assigned into four groups, of 6 animals in each group. Rats in the SCI group were given SCI surgery, animals in the SCI + LV group were given empty lentivirus (Hunan Fenghui Biotechnology Co., Ltd., Changsha, China) by intrathecal injection followed by SCI surgery, and rats in the SCI + LV-STIP1 group were intrathecally injected with the pLVX-IRESPuro vector (Hunan Fenghui Biotechnology Co., Ltd., Changsha, China) containing the coding sequence of STIP1 (1 × 10⁷ TU; File S1), followed by SCI surgery, while rats in the Sham group received abdominal aorta separation without clip closure alone. Rats received surgery 3 days post-injection with lentivirus. Following induction of anaesthesia by intraperitoneal injection of 50 mg/kg sodium pentobarbital and abdominal shaving, rats received laparotomy. Briefly, the rat abdominal aorta was exposed, and heparin (130 U/kg) was intravenously given to prevent blood clotting. Clamping was performed for 1 h and reperfusion for 0, 12 or 24 h. The rat body temperature was maintained at 36.5 ± 0.5°C. After clamping for 1 h and reperfusion for 24 h, the rats received neurological function scoring and sacrifice, and spinal cord (L2–L5) specimens were sampled for subsequent detections.

2.3 | Neurological function scoring

Following induction of ischaemia-reperfusion for 24 h, the motor function of rat hind limbs was recorded in each group according to the Basso, Beattie and Bresnahan (BBB) score.21,22 According to the presence of motor function defect, scores were assigned ranging from 0 to 21 points. Scores were evaluated by two investigators who were blinded to the grouping.

2.4 | Western blotting

Total protein was extracted from spinal cord specimen with RIPA lysis buffer (Beyotime, Haimen, China) with 1% phenylmethane sulfonyl fluoride (PMSF; Beyotime), and nuclear and cytoplasmic proteins were extracted with Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime). The concentration of total protein was
quantified using a BCA assay, and total proteins were then separated by SDS-PAGE. Subsequently, the blots were transferred onto polyvinylidene difluoride membranes (0.45 μm) (Thermo Fisher, Waltham, MA, USA), blocked with skim milk and incubated with the primary antibodies (Table 1) at 4°C overnight, while β-actin (cellular and cytoplasmic controls) and histone H3 (nuclear control) served as loading controls. Immunoblots were washed thrice in TBS with Tween-20, and the blots were incubated with corresponding secondary antibody at 37°C for 40 min. Then, the blots were visualized by using an ECL kit (Amersham Biosciences, Piscataway, NJ, USA).

2.5 | HE staining

Spinal cord specimens were fixed with 4% paraformaldehyde, washed with flow water and dehydrated with ethanol and xylene. Then, the tissue was embedded into paraffin and cut into 5-μm sections. Following deparaffination, the sections were stained with haematoxylin, differentiated with 1% hydrochloric acid/ethanol and counterstained with eosin. Finally, the sections were re-dehydrated and mounted with gum. The pathological changes were observed with a microscope (Olympus, Tokyo, Japan) at a magnification of 200x.

2.6 | Immunohistochemistry

Spinal cord specimens were made into paraffin-embedded sections as described above. After deparaffination, the sections were reacted with antigen repair buffer at boiling for 10 min. The sections were blocked with goat serum and incubated with mouse anti-human NeuN monoclonal antibody (1:100; lot number: ab104224; Abcam, Cambridge, UK), mouse anti-human Iba-1 monoclonal antibody (1:50; lot number: sc-32725; Santa Cruz Biotechnology, CA, USA) or rabbit anti-human STIP1 monoclonal antibody (1:100; lot number: AF9204, Affinity) at 4°C in the darkness overnight. After being washed in PBS, sections were incubated with the fluorescein isothiocyanate or Cy3-conjugated IgG secondary antibody (Beyotime) at temperature and counterstained with DAPI. Finally, sections were mounted with anti-fading reagent and observed with a fluorescent microscope at a magnification of 400x.

2.7 | Enzyme-linked immunosorbent assay

The tumour necrosis factor (TNF)-α and IL-6 levels were measured in rat spinal cord specimens with Rat ELISA kits for TNF-α or IL-6 (USCN, Wuhan, China) following the manufacturer’s protocols, and the TNF-α and IL-6 levels were quantified in the BV2 cell culture supernatant with Mouse ELISA kits for TNF-α or IL-6 (USCN) following the manufacturer’s instructions.

2.8 | Immunoprecipitation

BV2 cells were lysed with RIPA lysis buffer supplemented with 1% PMSF. The affinity agarose beads were pre-coated with mouse anti-human STIP1 monoclonal antibody (lot number: sc-393475; Santa Cruz Biotechnology) and mouse anti-human HSPA8 (lot number: sc-7298; Santa Cruz Biotechnology) or IgG antibody. The cell lysates were incubated with affinity agarose beads at 4°C for 2 h. After centrifugation, the sediment was collected and degenerated at boiling, and the supernatant was detected by SDS-PAGE as previously described.

2.9 | Ethical consideration

This study was approved by the Ethics Review Committee of Wuxi 9th Affiliated Hospital of Soochow University (approval number: KT2021011). All animal experiments were performed according to

| Antibody                                      | Dilution | Lot number | Manufacturer                     |
|-----------------------------------------------|----------|------------|----------------------------------|
| Rabbit anti-human STIP1 monoclonal antibody   | 1:1,000  | A0036      | ABclonal, Inc., Wuhan, China     |
| Rabbit anti-human NF-κB p65 polyclonal antibody| 1:1,000  | AF5006     | Affinity Biosciences; Changzhou, China |
| Rabbit anti-human IκBα polyclonal antibody    | 1:1,000  | AF6448     | Affinity Biosciences; Changzhou, China |
| Rabbit anti-human TNF-α polyclonal antibody   | 1:1,000  | DF6080     | Affinity Biosciences; Changzhou, China |
| Rabbit anti-human IL-6 polyclonal antibody    | 1:1,000  | DF6087     | Affinity Biosciences; Changzhou, China |
| Rabbit anti-human histone-H3 polyclonal antibody| 1:1,000  | 17168-1-AP | Proteintech Group; Wuhan, China |
| Mouse anti-human β-actin monoclonal antibody  | 1:2,000  | 60008-1-1  | Proteintech Group; Wuhan, China  |
the Guide for the Care and Use of Laboratory Animals (8th, NIH) and the State Regulations for Laboratory Animal Management in China.

2.10 | Statistics

All measurement data were described as mean ± SD, and all statistical analyses were performed using the software GraphPad Prism version 8.0 (GraphPad Software, Inc., La Jolla, CA, USA). Differences of means between groups were tested for statistical significance with Student’s t test, and comparisons among multiple groups were performed with one-way ANOVA followed by Bonferroni post hoc test. A p < 0.05 was considered statistically significant.

3 | RESULTS

3.1 | STIP1 expression is increased firstly followed by a reduction in rats after SCII

We firstly determined STIP1 expression in rat spinal cord specimens after SCII treatment using Western blotting and immunohistochemistry (Figure 1A), and we found a rapid increase in STIP1 expression after ischaemia followed by a gradual reduction after reperfusion (Figure 1B,C). The STIP1 expression was significantly lower in the SCII group than in the Sham group 24 h post-reperfusion (p < 0.001).

3.2 | STIP1 alleviates ischaemia/reperfusion-induced motor function impairment and neuronal injury in rat spinal cord

To investigate the effect of STIP1 on SCII, the lentivirus containing STIP1 coding sequences was intrathecally injected into rats and rats underwent SCII treatment 72 h post-injection (Figure 2A). Western blotting detected STIP1 overexpression in rat spinal cord specimens (Figure 2B), and SCII was found to cause conspicuous motor dysfunctions in rat hind limbs as revealed by BBB scoring (Figure 2C). HE staining showed loss of basophilic substances and decreased number of intact neurons in rat spinal cord specimens post-treatment with SCII, and these morphological changes were recovered to some degrees after STIP1 overexpression (Figure 2D). Immunohistochemical staining showed that SCII caused loss of NeuN-positive neurons, which was alleviated by STIP1 (Figure 2E).

3.3 | STIP1 ameliorates ischaemia/reperfusion-induced inflammation in rat spinal cord

Immunofluorescent staining detected elevated expression of Iba-1, a marker of activated microglia, in rat spinal cord after ischaemia-reperfusion treatment. Moreover, STIP1 was co-located with Iba-1, suggesting that STIP1 may be associated with microglia (Figure 3A). ELISA showed elevation of TNF-α and IL-6 levels in rat spinal cord following SCII treatment, and a decline after STIP1 overexpression (Figure 3B).

Then, we determined the expression of NF-κB signalling-associated proteins, and Western blotting revealed that SCII induced a reduction in IκBβ and cytoplasmic NF-κB p65 expression and a rise in nuclear NF-κB p65 protein in rat spinal cord, indicating activation of the NF-κB signalling pathway (Figure 3C,D). Nevertheless, elevated IκBβ expression and reduced nuclear NF-κB p65 expression were observed following administration with STIP1-overexpressed lentivirus, suggesting that STIP1 deactivates NF-κB signalling (Figure 3C,D).

3.4 | STIP1 restrains OGD-induced inflammation in microglial cells

Next, mouse microglia BV2 cells were used for detection of inflammation. First, BV2 cells were infected with the STIP1-overexpressed lentivirus and underwent OGD for 6 h and reperfusion for 24 h (Figure 4A). Western blotting determined reduced STIP1 expression in BV2 cells following OGD treatment, which was similar to the findings seen in rats (Figure 4B). Immunoprecipitation demonstrated that OGD treatment caused a rise in HSPA8 expression, and STIP1 was found to bind to HSPA8 (Figure 4C), which was consistent with previous reports. Upon STIP1 overexpression, IκBβ expression was increased and HSPA8 expression was decreased. Moreover, the binding activity between IκBβ and HSPA8 was reduced (Figure 4D,E). Since HSPA8 was reported to destabilize IκBβ, it is therefore hypothesized that STIP1 enhance IκBβ expression through competitively binding to HSPA8 and attenuating its destabilizing effects on IκBβ. Western blotting and immunohistochemistry revealed that OGD treatment led to degradation of IκBβ and nuclear translocation of NF-κB p65, which was abolished in BV2 cells to some degrees by STIP1 overexpression (Figure 4F-H). These results supported our hypothesis. Subsequently, we detected OGD-induced inflammation, and immunohistochemical staining revealed that OGD-induced Iba-1 up-regulation was recovered by STIP1 (Figure 4I). ELISA and Western blotting assays revealed that both the expression and secretion of TNF-α and IL-6 were promoted by OGD, and inhibited by STIP1 in BV2 cells (Figure 4J,K), which was consistent with the findings in rats.

4 | DISCUSSION

To date, the role of STIP1 in SCII remains unclear. This study, designed in both in vivo and in vitro assays, aimed to examine the effect of STIP1 on SCII and unravel the possible mechanisms. In this study, we found a rapid increase in STIP1 expression followed by a decline in rat spinal cord following SCII treatment, and STIP1 overexpression alleviated SCII-induced motor dysfunctions of hind
limbs, and neuronal loss and inflammation in spinal cord of rats. In vitro assay showed activation of microglial cells after SCII treatment, and co-location of STIP1 with microglia as revealed by immunoprecipitation, and STIP1 was found to restrain OGD-induced inflammation in BV2 cells. In addition, our data showed that STIP1 activated NF-κB signalling both in vivo and in vitro, and STIP1 led to elevated IκBβ expression, reduced HSPA8 expression and a reduced binding activity of IκBβ to HSPA8, suggesting that STIP1 competes with IκBβ to bind to HSPA8, and then suppresses NF-κB signalling.

Nuclear factor kappa B signalling is a central signalling in immune responses. In mammals, the NF-κB family is composed of five related transcription factors, including p50, p52, p65 (also termed RelA), c-Rel and RelB. These transcription factors share an N-terminal DNA-binding/dimerization domain, known as the Rel homology domain responsible for DNA binding and homo- and heterodimerization. NF-κB dimers bind to a variety of target DNA sequences called κB sites to modulate gene transcription through the recruitment of co-activators and co-repressors. In most cells, NF-κB complexes are inactive, residing predominantly in the cytoplasm in a complex with inhibitory IκB proteins (IκBα, IκBβ, IκBε, IκBζ, p100, p105, Bcl3 and IκBns). If the pathway is activated, the IκB protein is degraded and NF-κB dimers enter the nucleus to modulate target gene expression. The degradation of IκB is mediated by IκB kinase complex, which phosphorylates IκB and targets it for ubiquitin-proteasome degradation. It has been recently reported that knockdown of HSPA8 inhibited degradation of IκB and deactivated NF-κB signalling. In our study, STIP1 overexpression was found to cause an increase in IκB expression and deactivation of NF-κB signalling. The binding between STIP1 and HSPA8 has been previously reported. We hypothesized that STIP1 competed with IκB to bind to HSPA8. STIP1 overexpression induced a decrease in HSPA8 binding to IκB, resulting in stabilization of IκB and deactivation of NF-κB signalling. However, more studies are required to test our hypothesis.

Ischaemia-reperfusion may elicit injury in many organs, such as myocardial infarction, ischaemic stroke, acute kidney injury, trauma, circulatory arrest, sickle cell disease and sleep apnoea. Ischaemia-reperfusion is characterized by an initial restriction of blood supply followed by subsequent restoration of perfusion and concomitant reoxygenation. The restoration of blood flow and reoxygenation is frequently associated with an exacerbation of tissue injury and a profound inflammatory response. Ischaemia-reperfusion activates various programmes of cell death, including necrosis, apoptosis and autophagy-associated cell death. Ischaemia-reperfusion induces loss of neurons and activation of NF-κB signalling in rat spinal cord of rats, as well as activation of microglia. Microglia, a type of resident immune and macrophage cells, promotes neuro-regeneration by regulating growth factors, and promotes phagocytosis and scavenges damaged spinal tissues. Microglia-mediated inflammation contributes to scavage of damaged tissues. However, excessive inflammatory reaction may aggravate the injury. Minocycline, a macrolide antibiotic that could inhibit microglial activation, was reported to preserve hind limb motor function and restrain inflammatory factor production in mice with SCI. Our data showed that STIP1 ameliorated ischaemia/reperfusion-induced inflammation in rat spinal cord in vivo and OGD-induced inflammation in microglial cells in vitro by inhibiting NF-κB signalling activity, suggesting that STIP1 restrains SCI by inhibiting microglia-mediated inflammation.

Stress-induced phosphoprotein 1 may be produced by multiple cells, including astrocyte and microglia. In our study, STIP1
**FIGURE 2** STIP1 alleviates ischaemia/reperfusion-induced motor function impairment and neuronal injury in rat spinal cord. A, Ischaemia/reperfusion is given to rats; B, Western blotting detects STIP1 expression in rat spinal cord specimens after STIP1 overexpression; C, BBB scoring measures the motor function of rat hind limbs; D, HE staining detects the morphological changes of rat spinal cord. Scale bar =100 μm; E, immunohistochemical staining detects the expression of the neuron marker NeuN. Scale bar =50 μm. BBB, Basso, Beattie and Bresnahan; ***p < 0.001 versus the Sham group, ###p < 0.001 versus the SCII +LV group.

**FIGURE 3** STIP1 ameliorates ischaemia/reperfusion-induced inflammation in rat spinal cord. A, Immunohistochemical staining determines the expression and location of Iba-1 and STIP1. The arrows indicate co-location of STIP1 and Iba-1. Scale bar =50 μm; B, ELISA detects TNF-α and IL-6 secretion in rat spinal cord specimens following SCII treatment and STIP1 overexpression; C, Western blotting determines IκBβ expression in rat spinal cord specimens; D, Western blotting determines the cytoplasmic and nuclear expression of NF-κB p65. NF-κB, nuclear factor kappa B; SCII, spinal cord ischaemia-reperfusion injury; STIP1, stress-induced phosphoprotein 1; TNF, tumour necrosis factor. ***p < 0.001 versus the Sham group; *p < 0.05, ###p < 0.001 versus the SCII + LV group.
STIP1 restrains OGD-induced inflammation in microglial cells. A, BV2 cell treatments; B, Western blotting determines STIP1 expression in BV2 cells after OGD treatment; C, Immunoprecipitation detects the binding between STIP1 and HSPA8 in BV2 cells; D, Western blotting determines STIP1 expression after STIP1 overexpression; E, Immunoprecipitation detects the interaction between HSPA8 and IkBβ in BV2 cells; F, Western blotting detects IkBβ expression in BV2 cells; G, Western blotting detects cytoplasmic and nuclear NF-κB p65 levels in BV2 cells; H, Immunofluorescent staining detects the location of NF-κB p65. Scale bar = 50 μm; I, Immunofluorescent staining detects the expression of the microglia marker Iba-1. Scale bar = 50 μm; J, ELISA detects the secretion of inflammatory factors TNF-α and IL-6 in the cell culture supernatant; K, Western blotting determines TNF-α and IL-6 expression in BV2 cells after OGD treatment and STIP1 overexpression. NF-κB, nuclear factor kappa B; OGD, oxygen and glucose deprivation; SCII, spinal cord ischaemia-reperfusion injury; STIP1, stress-induced phosphoprotein 1; TNF, tumour necrosis factor. **p < 0.01, ***p < 0.001 versus the Sham group, #p < 0.05, ##p < 0.01, ###p < 0.001 versus the SCII + LV group.

FIGURE 4
was found to be co-located with Iba-1, a marker of microglia, confirming that STIP1 was expressed in microglial cells of rat spinal cord. Because of limited microglia in spinal cord, the co-localization of STIP1 and microglia was undetectable in rats in the Sham group. We detected elevated STIP1 expression followed by reduced expression in the rat spinal cord following ischaemia/reperfusion. However, a lot of neurons were lost, while microglia was activated in rats in the SCII group, leading to prominent co-localization of STIP1 and microglia in SCI rats. Nevertheless, the changes of STIP1 expression were not clear in rat neurons. It is therefore considered that the difference between the number of neurons and microglial cells causes diverse STIP1 expression in neurons and microglial cells. STIP1 has been identified to play a neural protective role by binding to prion protein to inhibit the binding of soluble amyloid-β oligomers to prion protein in mouse neurons.12 As a chaperone, STIP1 binds to HSPA8, which was also confirmed in our data. In addition, STIP1 induced an increase in IkB expression and a reduction in the binding of IkB to HSPA8, suggesting that STIP1 promotes IkB expression by occupying HSPA8 and then deactivates NF-κB signalling. In addition, STIP1 expression rapidly increased after ischaemia and then decreased gradually after reperfusion. It is therefore speculated that the elevation of STIP1 may be protective in ischaemic conditions, and this elevation is broken off by reoxygenation. Our data demonstrated that STIP plays a protective role after ischaemia-reperfusion in rat spinal cord and microglia, which supported our speculation.

5 | CONCLUSIONS

In summary, the results of the present study demonstrate that STIP1 restrains ischaemia/reperfusion-induced neuronal injury and inflammation by deactivating NF-κB signalling in rats and mouse microglia. Our findings may provide novel insights for the diagnosis and treatment of SCI.

ACKNOWLEDGEMENTS

This study was supported by the Precision Medicine Projects of the Wuxi Municipal Commission of Health (grant no. J202007).

CONFLICT OF INTEREST

The authors declare no conflict of interests.

AUTHOR CONTRIBUTION

Hongdou Jin: Formal analysis (equal); Investigation (equal); Writing-original draft (equal). Xin Ge: Conceptualization (equal); Funding acquisition (equal); Writing-review & editing (equal). Zhirong Huan: Formal analysis (equal); Investigation (equal). Hao Yao: Investigation (equal). Ce Xu: Investigation (equal). Jimin Cai: Investigation (equal).

CONSENT FOR PUBLICATION

All authors approve to publish this manuscript.

DATA AVAILABILITY STATEMENT

All data presented in this study are available upon request by contact with the corresponding author.

ORCID

Xin Ge https://orcid.org/0000-0003-1377-100X

REFERENCES

1. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002;359:417-425.
2. Singh A, Tetreault L, Kalsi-Ryan S, Nouri A, Fehlings MG. Global prevalence and incidence of traumatic spinal cord injury. Clin Epidemiol. 2014;6:309-331.
3. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:56-87.
4. Badihiwala JH, Wilson JR, Fehlings MG. Global burden of traumatic brain and spinal cord injury. Lancet Neurol. 2019;18:24-25.
5. Kiraz M, Demir E. A bibliometric analysis of publications on spinal cord injury during 1980–2018. World Neurosurg. 2020;136:e504-e513.
6. Anjum A, Yazid MD, Fauzi Daud M, et al. Spinal cord injury: pathophysiology, multimolecular interactions, and underlying recovery mechanisms. Int J Mol Sci. 2020;21:7533.
7. Khorsanizadeh MH, Yousefifard M, Eskian M, et al. Neurological recovery following traumatic spinal cord injury: a systematic review and meta-analysis. J Neurosurg Spine. 2019;30:683-699.
8. Oyinbo CA. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiol Exp (Wars). 2011;71:281-299.
9. Anwar MA, Al Shehabi TS, Eid AH. Inflammogenesis of secondary spinal cord injury. Front Cell Neurosci. 2016;10:98.
10. Karve IP, Taylor JM, Crack PJ. The contribution of astrocytes and microglia to traumatic brain injury. Br J Pharmacol. 2016;173:692-702.
11. Smith PD, Bell MT, Puskas F, et al. Preservation of motor function after spinal cord ischemia and reperfusion injury through microglial inhibition. Ann Thorac Surg. 2013;95:1647-1653.
12. Smith DF, Sullivan WP, Marion TN, et al. Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70. Mol Cell Biol. 1993;13:869-876.
13. Song Y, Masson DC. Independent regulation of Hsp70 and Hsp90 chaperones by Hsp70/Hsp90-organizing protein Sti1 (Hop1). J Biol Chem. 2005;280:34178-34185.
14. Wegele H, Hasbeck M, Reinstein J, Buchner J. Sti1 is a novel activator of the Ssa proteins. J Biol Chem. 2003;278:25970-25976.
15. Kubota H, Yamamoto S, Itoh E, et al. Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperones. 2010;15:1003-1011.
16. Odunuga OO, Longshaw VM, Blatch GL. Hop: more than an Hsp70/adaptor protein. BioEssays. 2004;26:1058-1068.
17. Ostapchenko VG, Beraldo FH, Mohammad AH, et al. The prion protein ligand, stress-inducible phosphoprotein 1, regulates amyloid-β oligomer toxicity. J Neurosci. 2013;33:16552-16564.
18. Lee S-D, Lai TW, Lin S-Z, et al. Role of stress-inducible protein-1 in recruitment of bone marrow derived cells into the ischemic brains. EMBO Mol Med. 2013;5:1227-1246.
19. Beraldo FH, Soares IN, Goncalves DF, et al. Stress-inducible phosphoprotein 1 has unique cochaperone activity during development and regulates cellular response to ischemia via the prion protein. FASEB J. 2013;27:3594-3607.
20. Zhu B, Li Y, Li M, et al. Dynamic proteome analysis of spinal cord injury after ischemia-reperfusion in rabbits by two-dimensional difference gel electrophoresis. Spinal Cord. 2013;51:610-615.
21. Zhao L, Zhai M, Yang XU, et al. Dexmedetomidine attenuates neuronal injury after spinal cord ischaemia-reperfusion injury by targeting the CNPY2-endoplasmic reticulum stress signalling. J Cell Mol Med. 2019;23:8173-8183.
22. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995;12:1-21.
23. Wang L, Dong H, Song G, et al. TXNDC5 synergizes with HSC70 to exacerbate the inflammatory phenotype of synovial fibroblasts in rheumatoid arthritis through NF-κB signaling. Cell Mol Immunol. 2018;15:685-696.
24. Hayden MS, Ghosh S. NF-kappaB in immunobiology. Cell Res. 2011;21:223-244.
25. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344-362.
26. Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17:1391-1401.
27. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
28. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med. 2009;361:1570-1583.
29. Haddad JJ. Oxygen-sensing mechanisms and the regulation of redox-responsive transcription factors in development and pathophysiology. Respir Res. 2002;3:26.
30. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA. 2006;103:18154-18159.
31. Herz J, Filiano AJ, Smith A, Yogeve N, Kipnis J. Myeloid cells in the central nervous system. Immunity. 2017;46:943-956.
32. Kroner A, Greenhalgh A, Zarruk J, et al. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron. 2014;83:1098-1116.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Jin H, Ge X, Huan Z, Yao H, Xu C, Cai J. Stress-induced phosphoprotein 1 restrains spinal cord ischaemia-reperfusion injury by modulating NF-κB signalling. J Cell Mol Med. 2021;25:11075-11084. doi:10.1111/jcmm.17030